Choksi Laboratories Ltd
BSE:526546
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (21.5), the stock would be worth ₹32.37 (68% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 67.7 | ₹101.8 |
0%
|
| 3-Year Average | 21.5 | ₹32.37 |
-68%
|
| 5-Year Average | 21.5 | ₹32.37 |
-68%
|
| Industry Average | 32.1 | ₹48.26 |
-53%
|
| Country Average | 49.7 | ₹74.85 |
-26%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
C
|
Choksi Laboratories Ltd
BSE:526546
|
709m INR | 67.7 | 38.1 | |
| UK |
|
Relx PLC
LSE:REL
|
49.1B GBP | 17.5 | 23.8 | |
| UK |
I
|
IHS Markit Ltd
F:0M3
|
37.9B EUR | 60 | 36.5 | |
| CA |
|
Thomson Reuters Corp
TSX:TRI
|
57.8B CAD | 36.7 | 27.8 | |
| IE |
|
Experian PLC
LSE:EXPN
|
25B GBP | 23 | 24.8 | |
| US |
|
Verisk Analytics Inc
NASDAQ:VRSK
|
25.1B USD | 9.1 | 27.6 | |
| CH |
|
SGS SA
SIX:SGSN
|
16.3B CHF | 9.9 | 24.6 | |
| US |
|
Equifax Inc
NYSE:EFX
|
20.7B USD | 14 | 29.7 | |
| US |
|
Leidos Holdings Inc
NYSE:LDOS
|
18.9B USD | 13.1 | 13 | |
| US |
U
|
UL Solutions Inc
NYSE:ULS
|
18.4B USD | 0 | 0 | |
| NL |
|
Wolters Kluwer NV
AEX:WKL
|
15B EUR | 7.3 | 11.5 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Choksi Laboratories Ltd
Glance View
Choksi Laboratories Ltd. engages in the business of research, development, and analytical testing. The company is headquartered in Indore, Madhya Pradesh. The firm operates through analytical testing. The company analyzes for its clients, or as regulatory requirement pharmaceuticals, food and agricultural products, construction materials, chemicals, calibration and environment monitoring services. The Company’s services include contract laboratory services, instrument calibration and validation services, environment management services, clinical research, consultancy, and assaying and hallmarking. Its contract laboratory services include pharmaceutical analysis, food and beverage analysis, water analysis and construction material analysis. The firm offers calibration services, including laboratory and on-site calibration for test equipment, process equipment and in many cases end-user equipment, plant shutdown calibration, and consultancy for setting up an in-house calibration laboratory.
